Two-year interim outcomes of the PALADIN study showed that sustained, continuous release of fluocinolone acetonide through the Iluvien implant resulted in significant reduction of mean central subfoveal thickness in diabetic macular edema.
In addition, vision was improved or stabilized with one or fewer supplemental treatments per year in the majority of patients with persistent or recurrent DME, and the IOP profile was predictable and manageable.
“Chronic low-grade inflammation is an early and central process in the development of diabetic macular edema. Corticosteroids address multiple
Uncategorized